North America Topical Drugs CDMO Market Size, Share & Trends Analysis Report By Product (Semi-solid, Liquid), By Service (Contract Development, Contract Manufacturing), By End Use, By Country, And Segment Forecasts, 2025 - 2030
This report can be delivered to the clients within 2 Business Days
North America Topical Drugs CDMO Market Growth & Trends
The North America topical drugs CDMO market size is anticipated to reach USD 27.22 billion by 2030, registering a CAGR of 10.88% from 2025 to 2030, according to a new report by Grand View Research, Inc. The increasing investment in R&D activities coupled with rising need for novel therapeutics for several dermatological conditions contributes to the growing demand for topical drugs CDMO market. Rising consumer preference for several topical solutions owing to ease of administration and minimized side effects are other factors supporting the growth of the market.
The growing need for novel innovation and new product developments are expected to improve the demand in the market, and competitive pressure & pricing concerns are driving companies to outsource new drug development & manufacturing. This is expected to drive overall market growth. Moreover, CDMOs are leveraging several advanced technologies such as nanotechnology to manipulate drug particles at the molecular level, enhancing drug stability and bioavailability. Moreover, microencapsulation techniques protect sensitive ingredients, allowing for controlled release and targeted drug delivery, amplifying therapeutic outcomes. Such technological advancements are accelerating market growth potential in North America.
CDMOs are actively involved in collaboration & partnerships with pharmaceutical companies to secure long-term contracts for innovative drug development and manufacturing of several topical formulations, which is expected to spur market demand. For instance, in January 2023, Swiss-American CDMO, a prominent provider specializing in topical skin care products, collaborated with LiquiGlide, the inventor of the EveryDrop dispensing platform. Through this collaboration, the company will utilize LiquiGlide’s innovative nontoxic slippery surface technology to eliminate friction between liquids & solids and product waste for consumer-packaged goods.
North America Topical Drugs CDMO Market Report Highlights
The Lubrizol Corporation
Cambrex Corporation
Contract Pharmaceuticals Limited
Bora Pharmaceutical CDMO
Ascendia Pharmaceuticals
Pierre Fabre S.A.
Piramal Pharma Solutions
DPT Laboratories, LTD.
MedPharm Ltd.
Zenvisionpharma
North America Topical Drugs CDMO Market Growth & Trends
The North America topical drugs CDMO market size is anticipated to reach USD 27.22 billion by 2030, registering a CAGR of 10.88% from 2025 to 2030, according to a new report by Grand View Research, Inc. The increasing investment in R&D activities coupled with rising need for novel therapeutics for several dermatological conditions contributes to the growing demand for topical drugs CDMO market. Rising consumer preference for several topical solutions owing to ease of administration and minimized side effects are other factors supporting the growth of the market.
The growing need for novel innovation and new product developments are expected to improve the demand in the market, and competitive pressure & pricing concerns are driving companies to outsource new drug development & manufacturing. This is expected to drive overall market growth. Moreover, CDMOs are leveraging several advanced technologies such as nanotechnology to manipulate drug particles at the molecular level, enhancing drug stability and bioavailability. Moreover, microencapsulation techniques protect sensitive ingredients, allowing for controlled release and targeted drug delivery, amplifying therapeutic outcomes. Such technological advancements are accelerating market growth potential in North America.
CDMOs are actively involved in collaboration & partnerships with pharmaceutical companies to secure long-term contracts for innovative drug development and manufacturing of several topical formulations, which is expected to spur market demand. For instance, in January 2023, Swiss-American CDMO, a prominent provider specializing in topical skin care products, collaborated with LiquiGlide, the inventor of the EveryDrop dispensing platform. Through this collaboration, the company will utilize LiquiGlide’s innovative nontoxic slippery surface technology to eliminate friction between liquids & solids and product waste for consumer-packaged goods.
North America Topical Drugs CDMO Market Report Highlights
- Based on product type, the semi-solid formulations segment dominated the market with a revenue share of more than 66.47% share in 2024, owing to numerous advantages including ease of administration and patient preference for topical drugs compared to the oral route of administration owing to several adverse effects, which is expected to drive segment demand
- Based on service type, the contract manufacturing segment is expected to grow at the substantial CAGR over the forecast period
- Based on sponsors, the pharmaceutical companies segment held the largest market share in 2024. Growing R&D investments by several pharmaceutical companies to develop and commercialize innovative topical drugs is anticipated to boost market revenue growth
- The U.S. dominated the North America topical drugs CDMO industry owing to factors such as strong presence of market participants in the region, government support for quality healthcare and high demand for cosmetic products
The Lubrizol Corporation
Cambrex Corporation
Contract Pharmaceuticals Limited
Bora Pharmaceutical CDMO
Ascendia Pharmaceuticals
Pierre Fabre S.A.
Piramal Pharma Solutions
DPT Laboratories, LTD.
MedPharm Ltd.
Zenvisionpharma
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Market Segmentation & Scope
1.2. Market Definitions
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Parent Market Analysis (Model 2)
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
CHAPTER 3. NORTH AMERICA TOPICAL DRUGS CDMO MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Technological advancements & growing R&D investments
3.2.1.2. Rising demand for topical medications
3.2.1.3. Expansion of manufacturing capacities and partnerships
3.2.2. Market Restraint Analysis
3.2.2.1. Compliance with strict regulatory requirements
3.2.2.2. Limited efficacy in certain conditions limits the adoption of topical products
3.3. Pricing Analysis
3.4. Topical Drugs CDMO Capacity Outlook
3.4.1. CDMO Manufacturing Container Capacity
3.4.2. Topical Drugs Container Capacity By Product Type
3.5. North America Topical Drugs CDMO Market Outlook By Product Category
3.5.1. North America Topical Drugs CDMO Market Share, By Product Category, 2024 (%)
3.5.2. Prescription Drugs
3.5.2.1. Segment Overview
3.5.2.2. Major Prescription Drugs, By Product Type
3.5.3. Generic Drugs
3.5.3.1. Segment Overview
3.5.3.2. Major Generic Drugs, By Product Type
3.5.4. Over-the-counter (OTC) Drugs
3.5.4.1. Segment Overview
3.5.4.2. Major OTC Drugs, By Product Type
3.6. North America Topical Drugs CDMO Market Analysis Tools
3.6.1. Porter’s Five Forces Analysis
3.6.2. PESTEL Analysis
3.6.3. COVID-19 Impact Analysis
3.6.4. U.S. Tariff Impact Analysis
CHAPTER 4. NORTH AMERICA TOPICAL DRUGS CDMO MARKET: PRODUCT ESTIMATES & TREND ANALYSIS
4.1. Product Market Share, 2024 & 2030
4.2. Segment Dashboard
4.3. North America Topical Drugs CDMO Market by Product Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.4.1. Semi-solid Formulations
4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.2. Creams
4.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.3. Ointments
4.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.4. Lotions
4.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.5. Others
4.4.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2. Liquid Formulations
4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2.2. Suspensions
4.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2.3. Solutions
4.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.3. Solid Formulations
4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.4. Transdermal Products
4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 5. NORTH AMERICA TOPICAL DRUGS CDMO MARKET: SERVICE ESTIMATES & TREND ANALYSIS
5.1. Service Market Share, 2024 & 2030
5.2. Segment Dashboard
5.3. North America Topical Drugs CDMO Market by Service Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.4.1. Contract Development
5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.1.2. Formulation Development
5.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.1.3. Analytical Testing
5.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.1.4. Stability Testing
5.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.1.5. Others
5.4.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2. Contract Manufacturing
5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2.2. Clinical
5.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2.3. Commercial
5.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 6. NORTH AMERICA TOPICAL DRUGS CDMO MARKET: END USE ESTIMATES & TREND ANALYSIS
6.1. End Use Market Share, 2024 & 2030
6.2. Segment Dashboard
6.3. North America Topical Drugs CDMO Market by End Use Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
6.4.1. Pharmaceutical Companies
6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.2. Biopharmaceutical Companies
6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.3. Others
6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 7. NORTH AMERICA TOPICAL DRUGS CDMO MARKET: COUNTRY ESTIMATES & TREND ANALYSIS
7.1. Country Market Share Analysis, 2024 & 2030
7.2. Country Market Dashboard
7.3. Country Market Snapshot
7.4. Market Size, & Forecasts, Trend Analysis, 2018 to 2030
7.5. U.S.
7.5.1. Key country dynamics
7.5.2. Competitive scenario
7.5.3. Regulatory framework
7.5.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
7.6. Canada
7.6.1. Key country dynamics
7.6.2. Competitive scenario
7.6.3. Regulatory framework
7.6.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
7.7. Mexico
7.7.1. Key country dynamics
7.7.2. Competitive scenario
7.7.3. Regulatory framework
7.7.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 8. COMPETITIVE LANDSCAPE
8.1. Company/Competition Categorization
8.1.1. Market Leaders
8.1.2. Emerging Players
8.2. Company Market Share/Assessment Analysis, 2024
8.3. Company Profiles
8.3.1. The Lubrizol Corporation
8.3.1.1. Company overview
8.3.1.2. Financial performance
8.3.1.3. Product/service benchmarking
8.3.1.4. Strategic initiatives
8.3.2. Cambrex Corporation
8.3.2.1. Company overview
8.3.2.2. Financial performance
8.3.2.3. Product/service benchmarking
8.3.2.4. Strategic initiatives
8.3.3. Contract Pharmaceuticals Limited
8.3.3.1. Company overview
8.3.3.2. Financial performance
8.3.3.3. Product/service benchmarking
8.3.3.4. Strategic initiatives
8.3.4. Bora Pharmaceutical CDMO
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product/service benchmarking
8.3.4.4. Strategic initiatives
8.3.5. Ascendia Pharmaceuticals
8.3.5.1. Company overview
8.3.5.2. Financial performance
8.3.5.3. Product/service benchmarking
8.3.5.4. Strategic initiatives
8.3.6. Pierre Fabre S.A.
8.3.6.1. Company overview
8.3.6.2. Financial performance
8.3.6.3. Product/service benchmarking
8.3.6.4. Strategic initiatives
8.3.7. Piramal Pharma Solutions
8.3.7.1. Company overview
8.3.7.2. Financial performance
8.3.7.3. Product/service benchmarking
8.3.7.4. Strategic initiatives
8.3.8. DPT Laboratories, LTD.
8.3.8.1. Company overview
8.3.8.2. Financial performance
8.3.8.3. Product/service benchmarking
8.3.8.4. Strategic initiatives
8.3.9. MedPharm Ltd.
8.3.9.1. Company overview
8.3.9.2. Financial performance
8.3.9.3. Product/service benchmarking
8.3.9.4. Strategic initiatives
8.3.10. Zenvisionpharma
8.3.10.1. Company overview
8.3.10.2. Financial performance
8.3.10.3. Product/service benchmarking
8.3.10.4. Strategic initiatives
1.1. Market Segmentation & Scope
1.2. Market Definitions
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Parent Market Analysis (Model 2)
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
CHAPTER 3. NORTH AMERICA TOPICAL DRUGS CDMO MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Technological advancements & growing R&D investments
3.2.1.2. Rising demand for topical medications
3.2.1.3. Expansion of manufacturing capacities and partnerships
3.2.2. Market Restraint Analysis
3.2.2.1. Compliance with strict regulatory requirements
3.2.2.2. Limited efficacy in certain conditions limits the adoption of topical products
3.3. Pricing Analysis
3.4. Topical Drugs CDMO Capacity Outlook
3.4.1. CDMO Manufacturing Container Capacity
3.4.2. Topical Drugs Container Capacity By Product Type
3.5. North America Topical Drugs CDMO Market Outlook By Product Category
3.5.1. North America Topical Drugs CDMO Market Share, By Product Category, 2024 (%)
3.5.2. Prescription Drugs
3.5.2.1. Segment Overview
3.5.2.2. Major Prescription Drugs, By Product Type
3.5.3. Generic Drugs
3.5.3.1. Segment Overview
3.5.3.2. Major Generic Drugs, By Product Type
3.5.4. Over-the-counter (OTC) Drugs
3.5.4.1. Segment Overview
3.5.4.2. Major OTC Drugs, By Product Type
3.6. North America Topical Drugs CDMO Market Analysis Tools
3.6.1. Porter’s Five Forces Analysis
3.6.2. PESTEL Analysis
3.6.3. COVID-19 Impact Analysis
3.6.4. U.S. Tariff Impact Analysis
CHAPTER 4. NORTH AMERICA TOPICAL DRUGS CDMO MARKET: PRODUCT ESTIMATES & TREND ANALYSIS
4.1. Product Market Share, 2024 & 2030
4.2. Segment Dashboard
4.3. North America Topical Drugs CDMO Market by Product Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.4.1. Semi-solid Formulations
4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.2. Creams
4.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.3. Ointments
4.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.4. Lotions
4.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.5. Others
4.4.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2. Liquid Formulations
4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2.2. Suspensions
4.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2.3. Solutions
4.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.3. Solid Formulations
4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.4. Transdermal Products
4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 5. NORTH AMERICA TOPICAL DRUGS CDMO MARKET: SERVICE ESTIMATES & TREND ANALYSIS
5.1. Service Market Share, 2024 & 2030
5.2. Segment Dashboard
5.3. North America Topical Drugs CDMO Market by Service Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.4.1. Contract Development
5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.1.2. Formulation Development
5.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.1.3. Analytical Testing
5.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.1.4. Stability Testing
5.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.1.5. Others
5.4.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2. Contract Manufacturing
5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2.2. Clinical
5.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2.3. Commercial
5.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 6. NORTH AMERICA TOPICAL DRUGS CDMO MARKET: END USE ESTIMATES & TREND ANALYSIS
6.1. End Use Market Share, 2024 & 2030
6.2. Segment Dashboard
6.3. North America Topical Drugs CDMO Market by End Use Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
6.4.1. Pharmaceutical Companies
6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.2. Biopharmaceutical Companies
6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.3. Others
6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 7. NORTH AMERICA TOPICAL DRUGS CDMO MARKET: COUNTRY ESTIMATES & TREND ANALYSIS
7.1. Country Market Share Analysis, 2024 & 2030
7.2. Country Market Dashboard
7.3. Country Market Snapshot
7.4. Market Size, & Forecasts, Trend Analysis, 2018 to 2030
7.5. U.S.
7.5.1. Key country dynamics
7.5.2. Competitive scenario
7.5.3. Regulatory framework
7.5.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
7.6. Canada
7.6.1. Key country dynamics
7.6.2. Competitive scenario
7.6.3. Regulatory framework
7.6.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
7.7. Mexico
7.7.1. Key country dynamics
7.7.2. Competitive scenario
7.7.3. Regulatory framework
7.7.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 8. COMPETITIVE LANDSCAPE
8.1. Company/Competition Categorization
8.1.1. Market Leaders
8.1.2. Emerging Players
8.2. Company Market Share/Assessment Analysis, 2024
8.3. Company Profiles
8.3.1. The Lubrizol Corporation
8.3.1.1. Company overview
8.3.1.2. Financial performance
8.3.1.3. Product/service benchmarking
8.3.1.4. Strategic initiatives
8.3.2. Cambrex Corporation
8.3.2.1. Company overview
8.3.2.2. Financial performance
8.3.2.3. Product/service benchmarking
8.3.2.4. Strategic initiatives
8.3.3. Contract Pharmaceuticals Limited
8.3.3.1. Company overview
8.3.3.2. Financial performance
8.3.3.3. Product/service benchmarking
8.3.3.4. Strategic initiatives
8.3.4. Bora Pharmaceutical CDMO
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product/service benchmarking
8.3.4.4. Strategic initiatives
8.3.5. Ascendia Pharmaceuticals
8.3.5.1. Company overview
8.3.5.2. Financial performance
8.3.5.3. Product/service benchmarking
8.3.5.4. Strategic initiatives
8.3.6. Pierre Fabre S.A.
8.3.6.1. Company overview
8.3.6.2. Financial performance
8.3.6.3. Product/service benchmarking
8.3.6.4. Strategic initiatives
8.3.7. Piramal Pharma Solutions
8.3.7.1. Company overview
8.3.7.2. Financial performance
8.3.7.3. Product/service benchmarking
8.3.7.4. Strategic initiatives
8.3.8. DPT Laboratories, LTD.
8.3.8.1. Company overview
8.3.8.2. Financial performance
8.3.8.3. Product/service benchmarking
8.3.8.4. Strategic initiatives
8.3.9. MedPharm Ltd.
8.3.9.1. Company overview
8.3.9.2. Financial performance
8.3.9.3. Product/service benchmarking
8.3.9.4. Strategic initiatives
8.3.10. Zenvisionpharma
8.3.10.1. Company overview
8.3.10.2. Financial performance
8.3.10.3. Product/service benchmarking
8.3.10.4. Strategic initiatives
LIST OF TABLES
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Global topical drugs CDMO: market estimates and forecasts, 2018 - 2030 (USD Billion)
Table 4 Global topical drugs: market estimates and forecasts, 2018 - 2030 (USD Billion)
Table 5 Development stages baseline model parameter estimates, By topical drugs
Table 6 Global topical drugs CDMO manufacturing container capacity/batch
Table 7 Global topical drugs capacity, by product type (per unit)
Table 8 Global topical drugs capacity, by container type (per unit)
Table 9 North America topical drugs CDMO market share, by product category, 2024 (%)
Table 10 List of major prescription drugs, by product type (2024)
Table 11 List of major generic drugs, by product type (2024)
Table 12 List of major OTC drugs, by product type (2024)
Table 13 North America topical drugs CDMO market estimates and forecasts, by product, 2018 - 2030 (USD Million)
Table 14 North America topical drugs CDMO market estimates and forecasts, by semi-solid formulations, 2018 - 2030 (USD Million)
Table 15 North America topical drugs CDMO market estimates and forecasts, by liquid formulation drugs, 2018 - 2030 (USD Million)
Table 16 North America topical drugs CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
Table 17 North America topical drugs CDMO market estimates and forecasts, by contract development, 2018 - 2030 (USD Million)
Table 18 North America topical drugs CDMO market estimates and forecasts, by contract manufacturing, 2018 - 2030 (USD Million)
Table 19 North America topical drugs CDMO market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
Table 20 North America topical drugs CDMO market estimates and forecasts, by country, 2018 - 2030 (USD Million)
Table 21 U.S. topical drugs CDMO market estimates and forecasts, by product, 2018 - 2030 (USD Million)
Table 22 U.S. topical drugs CDMO market estimates and forecasts, by semi-solid formulations, 2018 - 2030 (USD Million)
Table 23 U.S. topical drugs CDMO market estimates and forecasts, by liquid formulation drugs, 2018 - 2030 (USD Million)
Table 24 U.S. topical drugs CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
Table 25 U.S. topical drugs CDMO market estimates and forecasts, by contract development, 2018 - 2030 (USD Million)
Table 26 U.S. topical drugs CDMO market estimates and forecasts, by contract manufacturing, 2018 - 2030 (USD Million)
Table 27 U.S. topical drugs CDMO market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
Table 28 Canada topical drugs CDMO market estimates and forecasts, by product, 2018 - 2030 (USD Million)
Table 29 Canada topical drugs CDMO market estimates and forecasts, by semi-solid formulations, 2018 - 2030 (USD Million)
Table 30 Canada topical drugs CDMO market estimates and forecasts, by liquid formulation drugs, 2018 - 2030 (USD Million)
Table 31 Canada topical drugs CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
Table 32 Canada topical drugs CDMO market estimates and forecasts, by contract development, 2018 - 2030 (USD Million)
Table 33 Canada topical drugs CDMO market estimates and forecasts, by contract manufacturing, 2018 - 2030 (USD Million)
Table 34 Canada topical drugs CDMO market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
Table 35 Mexico topical drugs CDMO market estimates and forecasts, by product, 2018 - 2030 (USD Million)
Table 36 Mexico topical drugs CDMO market estimates and forecasts, by semi-solid formulations, 2018 - 2030 (USD Million)
Table 37 Mexico topical drugs CDMO market estimates and forecasts, by liquid formulation drugs, 2018 - 2030 (USD Million)
Table 38 Mexico topical drugs CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
Table 39 Mexico topical drugs CDMO market estimates and forecasts, by contract development, 2018 - 2030 (USD Million)
Table 40 Mexico topical drugs CDMO market estimates and forecasts, by contract manufacturing, 2018 - 2030 (USD Million)
Table 41 Mexico topical drugs CDMO market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
Table 42 Company profiles: Company overview
Table 43 Company profiles: Financial performance
Table 44 Company profiles: Service benchmarking
Table 45 Key company initiating service launches/upgrades
Table 46 Key companies initiating mergers/acquisitions/joint ventures
Table 47 Key companies initiating partnerships
Table 48 Key companies initiating expansion
Table 49 Key companies initiating others
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Global topical drugs CDMO: market estimates and forecasts, 2018 - 2030 (USD Billion)
Table 4 Global topical drugs: market estimates and forecasts, 2018 - 2030 (USD Billion)
Table 5 Development stages baseline model parameter estimates, By topical drugs
Table 6 Global topical drugs CDMO manufacturing container capacity/batch
Table 7 Global topical drugs capacity, by product type (per unit)
Table 8 Global topical drugs capacity, by container type (per unit)
Table 9 North America topical drugs CDMO market share, by product category, 2024 (%)
Table 10 List of major prescription drugs, by product type (2024)
Table 11 List of major generic drugs, by product type (2024)
Table 12 List of major OTC drugs, by product type (2024)
Table 13 North America topical drugs CDMO market estimates and forecasts, by product, 2018 - 2030 (USD Million)
Table 14 North America topical drugs CDMO market estimates and forecasts, by semi-solid formulations, 2018 - 2030 (USD Million)
Table 15 North America topical drugs CDMO market estimates and forecasts, by liquid formulation drugs, 2018 - 2030 (USD Million)
Table 16 North America topical drugs CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
Table 17 North America topical drugs CDMO market estimates and forecasts, by contract development, 2018 - 2030 (USD Million)
Table 18 North America topical drugs CDMO market estimates and forecasts, by contract manufacturing, 2018 - 2030 (USD Million)
Table 19 North America topical drugs CDMO market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
Table 20 North America topical drugs CDMO market estimates and forecasts, by country, 2018 - 2030 (USD Million)
Table 21 U.S. topical drugs CDMO market estimates and forecasts, by product, 2018 - 2030 (USD Million)
Table 22 U.S. topical drugs CDMO market estimates and forecasts, by semi-solid formulations, 2018 - 2030 (USD Million)
Table 23 U.S. topical drugs CDMO market estimates and forecasts, by liquid formulation drugs, 2018 - 2030 (USD Million)
Table 24 U.S. topical drugs CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
Table 25 U.S. topical drugs CDMO market estimates and forecasts, by contract development, 2018 - 2030 (USD Million)
Table 26 U.S. topical drugs CDMO market estimates and forecasts, by contract manufacturing, 2018 - 2030 (USD Million)
Table 27 U.S. topical drugs CDMO market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
Table 28 Canada topical drugs CDMO market estimates and forecasts, by product, 2018 - 2030 (USD Million)
Table 29 Canada topical drugs CDMO market estimates and forecasts, by semi-solid formulations, 2018 - 2030 (USD Million)
Table 30 Canada topical drugs CDMO market estimates and forecasts, by liquid formulation drugs, 2018 - 2030 (USD Million)
Table 31 Canada topical drugs CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
Table 32 Canada topical drugs CDMO market estimates and forecasts, by contract development, 2018 - 2030 (USD Million)
Table 33 Canada topical drugs CDMO market estimates and forecasts, by contract manufacturing, 2018 - 2030 (USD Million)
Table 34 Canada topical drugs CDMO market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
Table 35 Mexico topical drugs CDMO market estimates and forecasts, by product, 2018 - 2030 (USD Million)
Table 36 Mexico topical drugs CDMO market estimates and forecasts, by semi-solid formulations, 2018 - 2030 (USD Million)
Table 37 Mexico topical drugs CDMO market estimates and forecasts, by liquid formulation drugs, 2018 - 2030 (USD Million)
Table 38 Mexico topical drugs CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
Table 39 Mexico topical drugs CDMO market estimates and forecasts, by contract development, 2018 - 2030 (USD Million)
Table 40 Mexico topical drugs CDMO market estimates and forecasts, by contract manufacturing, 2018 - 2030 (USD Million)
Table 41 Mexico topical drugs CDMO market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
Table 42 Company profiles: Company overview
Table 43 Company profiles: Financial performance
Table 44 Company profiles: Service benchmarking
Table 45 Key company initiating service launches/upgrades
Table 46 Key companies initiating mergers/acquisitions/joint ventures
Table 47 Key companies initiating partnerships
Table 48 Key companies initiating expansion
Table 49 Key companies initiating others
LIST OF FIGURES
Fig. 1 North America topical drugs CDMO market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Commodity flow analysis
Fig. 9 Market snapshot
Fig. 10 Segment snapshot
Fig. 11 Competitive landscape snapshot
Fig. 12 Global topical drugs CDMO market outlook, 2023 (USD Billion)
Fig. 13 Global topical drugs market outlook, 2023 (USD Billion)
Fig. 14 North America topical drugs CDMO market dynamics
Fig. 15 Porter’s Five Forces analysis
Fig. 16 SWOT analysis, by factor (political & legal, economic and technological)
Fig. 17 North America Topical Drugs CDMO market: Product Type outlook and key takeaways
Fig. 18 North America Topical Drugs CDMO market: Product Type movement analysis
Fig. 19 Semi-solid formulations market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 20 Creams market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 21 Ointments market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 22 Lotions market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 23 Others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 24 Liquid formulations market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 25 Suspensions market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 26 Solutions market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 27 Solid formulations market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 28 Transdermal products market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 29 North America Topical Drugs CDMO market: Service type outlook and key takeaways
Fig. 30 North America Topical Drugs CDMO market: Service type movement analysis
Fig. 31 Contract development market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 32 Formulation development market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 33 Analytical testing market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 34 Stability testing market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 35 Others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 36 Contract manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 37 Clinical market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 38 Commercial market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 39 North America Topical Drugs CDMO market: sponsors outlook and key takeaways
Fig. 40 North America Topical Drugs CDMO market: sponsors movement analysis
Fig. 41 Pharmaceutical companies market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 42 Biopharmaceutical companies market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 43 Others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 44 North America Topical Drugs CDMO market revenue, by country, 2023 & 2030 (USD Million)
Fig. 45 Regional outlook, 2023 & 2030
Fig. 46 Regional Market Share Analysis, 2023 & 2030
Fig. 47 North America Topical Drugs CDMO market estimates and forecasts, 2018 - 2030 (USD million)
Fig. 48 Key country dynamics
Fig. 49 U.S. Topical Drugs CDMO market estimates and forecasts, 2018 - 2030 (USD million)
Fig. 50 Key country dynamics
Fig. 51 Canada Topical Drugs CDMO market estimates and forecasts, 2018 - 2030 (USD million)
Fig. 52 Market participant categorization
Fig. 53 Market participant categorization
Fig. 54 Heat map analysis
Fig. 1 North America topical drugs CDMO market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Commodity flow analysis
Fig. 9 Market snapshot
Fig. 10 Segment snapshot
Fig. 11 Competitive landscape snapshot
Fig. 12 Global topical drugs CDMO market outlook, 2023 (USD Billion)
Fig. 13 Global topical drugs market outlook, 2023 (USD Billion)
Fig. 14 North America topical drugs CDMO market dynamics
Fig. 15 Porter’s Five Forces analysis
Fig. 16 SWOT analysis, by factor (political & legal, economic and technological)
Fig. 17 North America Topical Drugs CDMO market: Product Type outlook and key takeaways
Fig. 18 North America Topical Drugs CDMO market: Product Type movement analysis
Fig. 19 Semi-solid formulations market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 20 Creams market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 21 Ointments market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 22 Lotions market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 23 Others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 24 Liquid formulations market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 25 Suspensions market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 26 Solutions market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 27 Solid formulations market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 28 Transdermal products market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 29 North America Topical Drugs CDMO market: Service type outlook and key takeaways
Fig. 30 North America Topical Drugs CDMO market: Service type movement analysis
Fig. 31 Contract development market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 32 Formulation development market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 33 Analytical testing market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 34 Stability testing market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 35 Others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 36 Contract manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 37 Clinical market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 38 Commercial market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 39 North America Topical Drugs CDMO market: sponsors outlook and key takeaways
Fig. 40 North America Topical Drugs CDMO market: sponsors movement analysis
Fig. 41 Pharmaceutical companies market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 42 Biopharmaceutical companies market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 43 Others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 44 North America Topical Drugs CDMO market revenue, by country, 2023 & 2030 (USD Million)
Fig. 45 Regional outlook, 2023 & 2030
Fig. 46 Regional Market Share Analysis, 2023 & 2030
Fig. 47 North America Topical Drugs CDMO market estimates and forecasts, 2018 - 2030 (USD million)
Fig. 48 Key country dynamics
Fig. 49 U.S. Topical Drugs CDMO market estimates and forecasts, 2018 - 2030 (USD million)
Fig. 50 Key country dynamics
Fig. 51 Canada Topical Drugs CDMO market estimates and forecasts, 2018 - 2030 (USD million)
Fig. 52 Market participant categorization
Fig. 53 Market participant categorization
Fig. 54 Heat map analysis
